Boundless Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Boundless Bio Common
BOLD Stock  USD 1.16  0.02  1.69%   
Boundless Bio's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Boundless Bio's valuation are provided below:
Market Capitalization
26 M
Earnings Share
(2.66)
There are over one hundred nineteen available fundamental signals for Boundless Bio Common, which can be analyzed over time and compared to other ratios. Investors should ensure to validate all of Boundless Bio's prevailing performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road. As of February 1, 2026, Enterprise Value is expected to decline to about (20.3 M)
Check Boundless Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Boundless Bio's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.9 M, Selling General Administrative of 11.9 M or Other Operating Expenses of 55.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.31. Boundless financial statements analysis is a perfect complement when working with Boundless Bio Valuation or Volatility modules.
  
Build AI portfolio with Boundless Stock
Check out the analysis of Boundless Bio Correlation against competitors.

Boundless Bio Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets150.9 M185.8 M161 M
Very volatile
Short and Long Term Debt Total57.5 M54.8 M11.9 M
Slightly volatile
Total Current Liabilities9.5 M7.3 M10.8 M
Slightly volatile
Property Plant And Equipment Net62 M59.1 M22.5 M
Slightly volatile
Current Deferred Revenue3.6 M3.5 M3.5 M
Pretty Stable
Accounts Payable1.1 M1.1 M2.3 M
Slightly volatile
Cash36 M23.9 M38.9 M
Pretty Stable
Non Current Assets Total26.7 M46.8 M34.5 M
Very volatile
Non Currrent Assets Other563.4 K593.1 K1.7 M
Slightly volatile
Cash And Short Term Investments121.8 M136.9 M123.5 M
Very volatile
Good Will2.9 M3.3 M3.6 M
Slightly volatile
Common Stock Shares Outstanding18.9 M15.3 M18.1 M
Slightly volatile
Short Term Investments85.7 M113 M84.6 M
Pretty Stable
Liabilities And Stockholders Equity150.9 M185.8 M161 M
Very volatile
Non Current Liabilities Total97.1 M54.8 M65.4 M
Slightly volatile
Other Current Assets2.4 M2 M2.9 M
Slightly volatile
Total Liabilities109.6 M64.1 M77.1 M
Slightly volatile
Total Current Assets124.2 M139 M126.4 M
Very volatile
Short Term Debt2.2 M2.5 M1.3 M
Slightly volatile
Intangible Assets6.4 M7.2 M7.9 M
Slightly volatile
Common Stock1.7 K1.8 K158.8 M
Slightly volatile
Capital Lease Obligations57.5 M54.8 M10.1 M
Slightly volatile
Property Plant And Equipment Gross66.5 M63.3 M14.9 M
Slightly volatile
Capital Stock1.6 K1.8 K2 K
Slightly volatile
Non Current Liabilities Other5.1 K5.4 K68.7 K
Slightly volatile
Net Working Capital107.8 M168.2 M85.1 M
Slightly volatile

Boundless Bio Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.9 M977.4 K1.8 M
Pretty Stable
Selling General Administrative11.9 M16.2 M12.5 M
Very volatile
Other Operating Expenses55.7 M65.9 M60 M
Pretty Stable
Research Development43.8 M49.7 M47.5 M
Pretty Stable
Total Operating Expenses55.6 M65 M59.9 M
Pretty Stable
Total Other Income Expense Net9.5 M9.1 M2.4 M
Slightly volatile
Net Interest Income9.5 M9.1 M2 M
Slightly volatile
Interest Income9.5 M9.1 M2 M
Slightly volatile
Cost Of Revenue1 M1.2 M789.8 K
Slightly volatile
Reconciled Depreciation1 M1.2 M789.8 K
Slightly volatile

Boundless Bio Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation4.5 M6.8 M3.8 M
Slightly volatile
Begin Period Cash Flow26.2 M21.8 M43.1 M
Slightly volatile
Depreciation1.9 M977.4 K1.8 M
Pretty Stable
Capital Expenditures2.2 M2.3 M8.9 M
Slightly volatile
Total Cash From Financing Activities101.5 M80.8 M102 M
Very volatile
End Period Cash Flow36.2 M24.4 M39.1 M
Pretty Stable
Other Cashflows From Investing Activities12.8 K14.4 K15.7 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation3.332.695.6755
Slightly volatile
Payables Turnover0.680.770.8374
Slightly volatile
Cash Per Share4.068.064.0281
Slightly volatile
Days Payables Outstanding343385421
Slightly volatile
Income Quality0.710.840.8578
Pretty Stable
Intangibles To Total Assets0.02690.02830.0509
Slightly volatile
Current Ratio10.7817.0812.502
Slightly volatile
Capex Per Share0.180.170.2313
Slightly volatile
Interest Debt Per Share2.652.520.5364
Slightly volatile
Debt To Assets0.220.210.0556
Slightly volatile
Days Of Payables Outstanding343385421
Slightly volatile
Ebt Per Ebit1.061.030.9864
Very volatile
Long Term Debt To Capitalization0.01720.01210.0154
Slightly volatile
Quick Ratio10.7817.0812.502
Slightly volatile
Net Income Per E B T0.780.880.9586
Slightly volatile
Cash Ratio4.283.764.1397
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.211.21.1958
Slightly volatile
Debt Ratio0.220.210.0556
Slightly volatile

Boundless Bio Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap364256348
Slightly volatile

Boundless Fundamental Market Drivers

About Boundless Bio Financial Statements

Boundless Bio stakeholders use historical fundamental indicators, such as Boundless Bio's revenue or net income, to determine how well the company is positioned to perform in the future. Although Boundless Bio investors may analyze each financial statement separately, they are all interrelated. For example, changes in Boundless Bio's assets and liabilities are reflected in the revenues and expenses on Boundless Bio's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Boundless Bio Common. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue3.5 M3.6 M
Cost Of Revenue1.2 M1 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
CCitigroup
SSentinelOne
When determining whether Boundless Bio Common is a strong investment it is important to analyze Boundless Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Boundless Bio's future performance. For an informed investment choice regarding Boundless Stock, refer to the following important reports:
How To Invest In Boundless
Details
Is Boundless Stock a good investment?
Details
What is Boundless Bio's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Boundless Bio Correlation against competitors.
You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Will Biotechnology sector continue expanding? Could Boundless diversify its offerings? Factors like these will boost the valuation of Boundless Bio. Projected growth potential of Boundless fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Boundless Bio data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(2.66)
Return On Assets
(0.25)
Return On Equity
(0.45)
The market value of Boundless Bio Common is measured differently than its book value, which is the value of Boundless that is recorded on the company's balance sheet. Investors also form their own opinion of Boundless Bio's value that differs from its market value or its book value, called intrinsic value, which is Boundless Bio's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Boundless Bio's market value can be influenced by many factors that don't directly affect Boundless Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
It's important to distinguish between Boundless Bio's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Boundless Bio should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Boundless Bio's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY